The publication of clinical data updates, especially in a high-profile event like the EHA Congress, is typically viewed positively by investors as it demonstrates progress in the company's pipeline. For a biopharmaceutical company like Autolus Therapeutics, advancements in clinical trials or positive data about their therapies can lead to increased investor confidence and potentially positive stock price movement in the short term. However, the actual impact on the stock price will depend on the details of the data presented and the market's perception of its significance.